Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $585.00

Vertex Pharmaceuticals (NASDAQ:VRTX) had its target price lifted by Citigroup from $575.00 to $585.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the pharmaceutical company’s stock.

A number of other research firms also recently issued reports on VRTX. Morgan Stanley reissued an “overweight” rating and set a $570.00 price target on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $590.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Stifel Nicolaus lifted their price objective on Vertex Pharmaceuticals from $445.00 to $466.00 and gave the company a “hold” rating in a research note on Friday, February 13th. Barclays boosted their target price on Vertex Pharmaceuticals from $606.00 to $607.00 and gave the stock an “overweight” rating in a report on Tuesday, February 17th. Finally, Jefferies Financial Group began coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday. They set a “buy” rating and a $580.00 target price for the company. Twenty-three analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $553.36.

Vertex Pharmaceuticals Stock Down 2.9%

NASDAQ:VRTX opened at $478.13 on Tuesday. The company has a market cap of $121.46 billion, a P/E ratio of 31.19, a P/E/G ratio of 2.10 and a beta of 0.31. The firm’s 50 day moving average is $469.68 and its two-hundred day moving average is $437.20. Vertex Pharmaceuticals has a fifty-two week low of $362.50 and a fifty-two week high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.05 by ($0.02). The company had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm earned $3.98 earnings per share. Research analysts forecast that Vertex Pharmaceuticals will post 15.63 earnings per share for the current fiscal year.

Insider Activity at Vertex Pharmaceuticals

In related news, EVP Mark E. Bunnage sold 2,021 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total transaction of $930,529.03. Following the sale, the executive vice president directly owned 12,914 shares in the company, valued at approximately $5,945,993.02. This trade represents a 13.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Duncan Mckechnie sold 4,910 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $487.65, for a total value of $2,394,361.50. Following the transaction, the executive vice president directly owned 17,559 shares in the company, valued at $8,562,646.35. This trade represents a 21.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 91,156 shares of company stock valued at $42,845,497 over the last 90 days. Corporate insiders own 0.20% of the company’s stock.

Institutional Trading of Vertex Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Motiv8 Investments LLC acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth $26,000. Swiss RE Ltd. acquired a new stake in Vertex Pharmaceuticals during the 4th quarter valued at $28,000. Chesapeake Asset Management LLC increased its stake in Vertex Pharmaceuticals by 110.0% during the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after buying an additional 33 shares during the period. Eagle Bay Advisors LLC purchased a new stake in Vertex Pharmaceuticals during the 4th quarter worth $29,000. Finally, IMG Wealth Management Inc. lifted its holdings in Vertex Pharmaceuticals by 277.8% in the 4th quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock worth $31,000 after buying an additional 50 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer raised its price target to $600, signaling meaningful upside from current levels and adding institutional momentum. Oppenheimer Raises Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $600.00
• Positive Sentiment: Bank of America reiterated/issued a bullish view that the stock is positioned to rise, supporting demand from fundamental analysts. Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, Bank of America Analyst Says
• Positive Sentiment: Citigroup likewise published a positive forecast for VRTX, adding to the cluster of buy-side endorsements. Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, Citigroup Analyst Says
• Positive Sentiment: Morgan Stanley projected strong price appreciation, further cementing a consensus of elevated analyst expectations. Morgan Stanley Forecasts Strong Price Appreciation for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock
• Positive Sentiment: Truist raised its price target to $525 and kept a buy rating, another near‑term upside signal from a major sell‑side shop. Benzinga
• Positive Sentiment: News reports show the stock recently spiked (up ~9–10%) on an analyst upgrade, indicating momentum-driven buying can be swift. Vertex Pharmaceuticals (NASDAQ:VRTX) Trading 9.9% Higher on Analyst Upgrade
• Positive Sentiment: Clinical catalyst: a Vertex drug reduced proteinuria in a Phase III IgA nephropathy trial — a meaningful development that could expand the pipeline and long‑term revenue potential. Vertex drug cuts proteinuria in Phase III IgA nephropathy trial
• Neutral Sentiment: Vertex presented at Barclays’ healthcare conference (transcript available) — useful for detail on pipeline timelines and management guidance but not an immediate price mover by itself. Vertex Pharmaceuticals Incorporated (VRTX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Coverage note: articles report a rising biotech weighting/focus in Nasdaq indexes, which can support longer‑term passive demand for VRTX but is not an immediate earnings catalyst. Vertex Pharmaceuticals (NASDAQ:VRTX) Biotech Focus Rises In Nasdaq Index
• Negative Sentiment: Despite the bullish notes, the stock has pulled back and printed a larger intraday decline than the market in recent sessions, reflecting profit‑taking and short‑term volatility. Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
• Negative Sentiment: Some commentary flagged that while price moves have been strong, recent earnings‑estimate revision trends may limit near‑term follow‑through. Vertex (VRTX) Moves 8.3% Higher: Will This Strength Last?

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.